TOPT241122P30000
- 0.00
- 0.000.00%
iShares Top 20 U.S. Stocks ETF Newsroom
Our Number One Name: Tesla
Tradepulse Power Inflow Alert: Eli Lilly & Company Climbs Over 22 Points After Alert
S&P 500, Dow Hit Records, Trump Tariffs to Cost Hundreds of Billions | Wall Street Today
Elon Musk Is Responsible For Palantir Stock Rally, Jim Cramer Says
Consumer Stocks Enter the Limelight With Black Friday and Cyber Monday Around the Corner
Retail Wrap: Holiday Shopping Season Kids off With Flurry of Retail Earnings
Philips And AWS Expand Strategic Collaboration To Advance HealthSuite Cloud Services And Power Generative AI Workflows
19,000 Bans And Counting, But Players Say Cheating Still Dominates Call Of Duty Black Ops 6
Wolfe's Most Shorted 'Hit List' – FSLR, BE, WBA, SJM
Nvidia Blackwell Supplier Vishay Intertechnology Likey To See Upside Courtesy Of AI Frenzy: Analyst
Amgen's weight loss drug has a remarkable 20% reduction effect, but with high side effects, causing the stock price to plummet by 12.3% at one point!
Although the weight loss effect of amgen's MariTide drug met expectations, the high side effects, lower than eli lilly and co's Zepbound, and the trial results falling below Wall Street's high expectations, led to amgen's stock price plunging over 12.3% on Tuesday, far behind eli lilly and co and novo-nordisk a/s, which benefited from the Biden policy rise at the same time. In a one-year trial, MariTide helped non-diabetic patients lose up to 20% of their weight, comparable to the maximum dose effect of eli lilly's Zepbound. However, the side effects are significant, with about 11% of patients dropping out of the trial due to side effects, higher than eli lilly's 7%.
Stocks Mixed Ahead Of Fed Minutes, Mexican Peso Tumbles To Over 2-Year Lows On Tariffs Fears: What's Driving Markets Tuesday?
10 Consumer Discretionary Stocks Whale Activity In Today's Session
10 Information Technology Stocks Whale Activity In Today's Session
Amazon Dominates Holiday Shopping As Black Friday Spending Soars: Goldman Sachs
The Biden administration has proposed covering weight loss medications under Medicare, while Trump's team may become the biggest obstacle.
①The Biden administration has proposed expanding the coverage of federal medical care and medical subsidies to include weight loss drugs; ②The White House claims that these drugs can prevent type 2 diabetes, lower the risk of cardiovascular diseases such as heart disease, but currently they are too expensive for Americans. ③This proposal may be blocked by the Trump administration taking office next year, as Senator Kennedy opposes weight loss drugs.
Meta to Face FTC Trial in April Over Instagram and WhatsApp Acquisitions - Reuters
Vishay Jumps After Named Winner on Nvidia AI Server Demand: TF
BTIG's Krinsky: 'It's Time to Look at Restaurants' – EAT Reaches All-time High
Apple Faces Uphill Task to Launch AI Model for IPhones in China - Report